skin lesions and itch for up to a year.1Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8

“Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development, and social confidence. This burden also often extends to caregivers who can experience anxiety, stress, and sleep loss. In our study, nemolizumab demonstrated a clinically meaningful benefit in children with moderate-to-severe atopic dermatitis, helping to reduce skin lesions and itch up to one year, and had a similar safety profile as
=*=*=*=*=*=
当前为第2/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页